There is no single “best” HIV medication, but U.S. treatment guidelines give their strongest recommendation to three specific regimens for most people starting treatment. All three are built around a newer class of drugs called integrase inhibitors, which block HIV from inserting its genetic code into your immune cells. These regimens are highly effective, well-tolerated, and in some cases available as a single daily pill.
The Three Recommended Starting Regimens
The U.S. Department of Health and Human Services gives its highest confidence rating to these initial regimens for most people with HIV:
- Biktarvy (bictegravir/tenofovir alafenamide/emtricitabine): A single pill taken once daily. It combines an integrase inhibitor with two other antivirals in one tablet, making it one of the simplest regimens available.
- Dolutegravir plus two antivirals (tenofovir alafenamide or tenofovir disoproxil fumarate, combined with emtricitabine or lamivudine): This uses a different integrase inhibitor and may involve one or two pills daily depending on the specific combination.
- Dovato (dolutegravir/lamivudine): A two-drug regimen in a single daily pill. It contains fewer medications than the other options, which can reduce long-term side effects for some people.
Dovato comes with a few restrictions. It’s not recommended if your viral load is above 500,000 copies per milliliter, if you have a hepatitis B co-infection, or if your doctor hasn’t yet received the results of your resistance testing. For everyone else, it performs comparably to three-drug regimens in clinical trials.
Why Integrase Inhibitors Are Preferred
All three recommended regimens center on integrase inhibitors because they work quickly, have relatively few drug interactions, and cause fewer side effects than older HIV drug classes like protease inhibitors or NNRTIs. Integrase inhibitors block a specific HIV enzyme that the virus needs to splice its DNA into your immune cells. Without that step, the virus can’t hijack your cells to make copies of itself.
The two integrase inhibitors in the current guidelines, bictegravir and dolutegravir, are considered “second-generation,” meaning they have a higher barrier to resistance. That makes it harder for the virus to develop mutations that would render the medication ineffective.
What Successful Treatment Looks Like
The goal of HIV treatment is to reduce the virus in your blood to undetectable levels, generally defined as fewer than 20 copies per milliliter. At that point, the virus can’t damage your immune system and can’t be transmitted sexually. Most people who start one of the recommended regimens and take it consistently reach undetectable status within a few months.
Your immune health is tracked through CD4 cell counts. A healthy response typically means your CD4 count rises by 50 to 150 cells in the first year, with the fastest gains in the first three months. After that, counts tend to climb by 50 to 100 cells per year until they stabilize. If your CD4 count was relatively high when you started treatment, you can expect it to return to near-normal levels over time.
Weight Gain and Metabolic Effects
The most talked-about side effect of modern HIV treatment is weight gain. Pooled data from eight randomized controlled trials found that roughly 13% of people starting treatment experienced more than 10% body weight gain within the first year. This effect is most pronounced with bictegravir, dolutegravir, and tenofovir alafenamide (the newer form of tenofovir found in Biktarvy and many combination pills).
This isn’t just a cosmetic concern. People who gained more than 10% of their body weight in the first year of treatment showed higher rates of type 2 diabetes, metabolic syndrome, and cardiovascular events in follow-up studies. Regimens that use the older form of tenofovir (tenofovir disoproxil fumarate) tend to cause less weight gain, though that version can be harder on the kidneys and bones over time. Your provider will weigh these tradeoffs based on your individual health profile.
Two-Drug vs. Three-Drug Regimens
For decades, standard HIV treatment required three active drugs. The two-drug option, Dovato, represents a shift in that thinking. Clinical trials showed that people who switched from a stable three-drug regimen to dolutegravir plus lamivudine maintained viral suppression just as well. Those who switched also saw improvements in bone density (particularly if they had previously been on tenofovir disoproxil fumarate) and slight improvements in insulin resistance.
A two-drug regimen means less total medication in your body, which can matter over decades of treatment. But it’s not appropriate for everyone. You need confirmed viral suppression, no resistance to either drug, no hepatitis B co-infection, and no history of treatment failure. Your provider will check all of these before recommending a switch.
The Injectable Option
If you’d rather not take a daily pill, there’s now a long-acting injectable regimen that combines cabotegravir and rilpivirine. It’s given as two shots in the buttocks, either every four weeks or every eight weeks, depending on the schedule you and your provider choose. Each visit has a seven-day window on either side of the target date.
To qualify, you need to already have an undetectable viral load, no history of treatment failure, and no known resistance to either drug in the injection. The injectable isn’t a first-line option for people just starting treatment. It’s designed for people who are already doing well on oral medication and want to move away from daily pills.
Resistance Testing Before You Start
Before your first prescription, your provider will order a genotypic resistance test. This looks at the virus’s genetic code to identify mutations that might make certain drugs ineffective. Standard testing checks for resistance to reverse transcriptase inhibitors and protease inhibitors. If there’s any reason to suspect integrase inhibitor resistance, such as prior use of injectable cabotegravir for prevention, integrase gene testing is added.
This step matters because HIV mutates frequently, and some people acquire a strain that already carries resistance mutations. Starting the wrong regimen could allow the virus to keep replicating and accumulate even more resistance, narrowing future treatment options.
Treatment During Pregnancy
The same integrase inhibitor-based regimens recommended for most adults are also preferred during pregnancy. Dolutegravir or bictegravir combined with tenofovir and emtricitabine (or lamivudine) are the first choices. Dovato is considered an alternative rather than preferred during pregnancy, and only when specific conditions are met, including a viral load under 500,000 and confirmed drug susceptibility.
For pregnant individuals who previously used injectable cabotegravir for HIV prevention, guidelines recommend a protease inhibitor-based regimen instead, because of the possibility of resistance to integrase inhibitors.
Paying for HIV Medication
HIV medications can cost thousands of dollars per month without insurance, but several programs exist to close that gap. The AIDS Drug Assistance Program (ADAP), funded through the Ryan White HIV/AIDS Program, provides FDA-approved HIV medications to low-income individuals with limited or no insurance. Each state runs its own ADAP and sets its own financial eligibility threshold, typically based on a percentage of the federal poverty level. You must have an HIV diagnosis and live in the state where you apply.
ADAP funds can also be used to purchase health insurance for eligible clients and to support services that help with medication adherence and monitoring. Most drug manufacturers also offer patient assistance programs with their own eligibility criteria, which your clinic or case manager can help you navigate.